If approved, the company is confident in its ability to Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA ...

Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial, reinforcing its ...

This marks AbbVie’s second major siRNA deal following its $1.4bn acquisition of Aliada Therapeutics last year.

lepodisiran, is expected to protect millions of people from heart attacks and strokes by lowering a little-known risk factor in the blood. Made by pharmaceutical giant Eli Lilly, the drug lowers ...

Both are antisense-based therapeutics. Eli Lilly meanwhile has an RNA interference drug lepodisiran that could be dosed once a year is in phase 3, as well as a daily oral candidate called ...

There is a new drug out "lepodisiran" that is in the early phases ... It still will have a certain group it targets. Yet Eli Lilly will likely try to market it for who knows what.

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...